



Chugai Pharmabody Research

At the forefront of global research

A subsidiary of Japan's leading pharma company
Chugai Pharmaceutical



Unlocking breakthroughs in drug discovery to
address global unmet medical needs since 2012



PROPRIETARY TECHNOLOGIES

Unlike conventional antibodies which has a limited number of targets, our technology in antibody engineering and cyclic peptides allows us to expand the drug target universe to discover novel treatments



STRATEGIC LOCATION

Located in Biopolis, Singapore's world-class biomedical research hub, we are well positioned to tap on the holistic ecosystem to continuously develop new drug therapies



EXPERTS IN R&D

Our highly-experienced team of scientists have strong R&D capabilities across the entire spectrum of the drug discovery process



Our goal is to deliver patient-centric healthcare. We can do this by leveraging on our proprietary technologies to make better and safer therapeutics that can transform patients' lives, and to do it faster.



Hideaki Shimada, Chief Executive Officer, (2021 January - 2025 June)
Chugai Pharmabody Research



Location

3 Biopolis Drive
#07-11 to 16, Synapse
Singapore 138623



Contact details

Tel : +65 6933 4888
Fax : +65 6684 2257
contact@chugai-pharmabody.com

